天津护理 ›› 2025, Vol. 33 ›› Issue (6): 651-655.DOI: 10.3969/j.issn.1006-9143.2025.06.005

• 论著 • 上一篇    下一篇

复发难治性淋巴瘤患者接受嵌合抗原受体 T 细胞临床试验真实体验的质性研究

李文慧 贺瑾 冯丽娜 孙丽君   

  1. (天津医科大学肿瘤医院 国家恶性肿瘤临床医学研究中心 天津市肿瘤防治重点实验室 天津市恶性肿瘤临床医学研究中心,天津 300060)
  • 出版日期:2025-12-28 发布日期:2025-12-17
  • 基金资助:
    天津市医学重点学科建设项目(TJYXZDXK-011A)

Qualitative study on the real experience of patients with relapsed and refractory lymphoma receiving CAR-T clinical trial

LI Wenhui,HE Jin,FENG Lina,SUN Lijun   

  1. (Tianjin Medical University Cancer Institute & Hospital, Tianjin 300060)
  • Online:2025-12-28 Published:2025-12-17

摘要: 目的:了解复发难治性淋巴瘤患者接受嵌合抗原受体 T(Chimeric Antigen Receptor T,CAR-T)细胞治疗的真实体验,为采取有针对性护理干预提供参考。方法:采用描述性现象学研究方法,选取 2023 年 1 月 2 日至 2024 年 2 月 1 日在天津市某三级甲等医院淋巴瘤内科病区接受 CAR-T 临床试验的 13 例复发难治性淋巴瘤患者进行半结构式访谈,并运用 Colaizzi 7 步分析法进行资料分析、总结、归纳。结果:13 例复发难治性淋巴瘤患者接受 CAR-T 临床试验真实体验可归纳为感知试验获益与风险(淋巴瘤相关不适症状缓解或消失、CAR-T 细胞治疗相关短期症状、CAR-T 细胞治疗后中长期症状困扰)、多重复杂性心理体验(自我矛盾与冲突贯穿全程、创伤性应激障碍及创伤后成长并存、对治疗呈多样化期望心理)以及主动寻求多元化支持(关注治疗相关信息、渴望延续性专业医疗服务、希望获得家庭支持)3 个主题。结论:复发难治性淋巴瘤患者接受 CAR-T 细胞治疗中存在多方面的体验,医护人员应根据患者的具体情况,制定具有针对性的护理策略,助其早日康复,回归正常生活。

关键词: 复发难治性淋巴瘤, CAR-T 细胞疗法, 临床试验, 真实体验, 质性研究

Abstract: Objective: To understand the real experience of patients with relapsed and refractory lymphoma receiving chimeric antigen receptor T(CAR-T) cell therapy, and to provide references and suggestions for taking targeted nursing intervention. Methods: The descriptive phenomenological design was adopted in the study. Thirteen patients with relapsed and refractory lymphoma who received CAR-T clinical trials in the lymphoma ward of a gade A tertiary cancer hospital in Tianjin from January 2,2023 to February 1,2024 were interviewed by semi-structured methods. The data was analyzed, summarized and induced by Colaizzi 7-step analysis method. Results: The real experience of thirteen patients with relapsed and refractory lymphoma receiving CAR-T clinical trial can be summarized into three themes, including perceived trial benefits and risks (remission or disappearance of discomfort symptoms related to lymphoma, short-term symptoms related to CAR-T cell therapy, and long-term symptoms after CAR-T cell therapy), multiple complex psychological experiences (self-contradiction and conflict running through the whole process, traumatic stress disorder and post-traumatic growth coexisting, showing diversified expectations for treatment), and actively seeking diversified support (paying attention to treatment -related information, longing for continuity of professional medical services, and hoping to obtain family support). Conclusion: Patients with relapsed and refractory lymphoma have many experiences in CAR-T cell therapy. Medical staff should formulate targeted nursing strategies according to patients′ specific conditions to help them recover as soon as possible and return to normal life.

Key words: Relapsed and refractory lymphoma, CAR-T cell therapy, Clinical trial, Real experience, Qualitative research

中图分类号: